Join

or

Existing user? Login

Cancer care

Sort by: Newest first Oldest first A-Z Z-A

  • Tyrosine kinase inhibitor

    Pharmacokinetic considerations and challenges in oral anticancer drug therapy Subscription

    A review of the pros and cons of oral anticancer drug therapy, as well as the pharmacokinetic barriers and potential solutions to oral chemotherapy in the home.

  • SEM of tumour in lung

    Lung cancer: advances in management and therapy Subscription

    An overview of traditional and emerging immunotherapy-based targets and treatments available for lung cancer, their side effects and the impact immune checkpoint inhibitors have had on the treatment of non–small-cell lung cancer.

  • Digitalised illustration of DNA in pill representing personalised medicine

    Genomic medicine is going mainstream and pharmacists need to be prepared Subscription

    The 100,000 Genome Project is driving the move from a ‘one size fits all’ approach to treatment, towards personalised, or precision, medicine. Genetic information is also being used by pharmaceutical companies to help speed up drug discovery and development, and reduce the associated costs. Pharmacists will have an important role to play when genomic medicine goes mainstream.

  • Andrew Godfrey running

    Multiple myeloma: an expensive revolution Subscription

    New treatments for this rare form of cancer have transformed patient survival rates, but the benefits have come with huge costs.

  • Micrograph of multiple myeloma tumour cells (green) and bone cells (red) growing on a scaffold made of silk protein (purple), designed to resemble bone material

    Multiple myeloma: pharmacological management Subscription

    Although multiple myeloma is currently regarded as being incurable in the majority of patients, the outlook for patients diagnosed with the condition has improved markedly over the past 40 years, with survival rates quadrupling. Significant advances in both treatment and supportive therapies have contributed to these improved outcomes and are discussed in this article.

  • Teenager gets an HPV vaccine injection

    The impact of the human papillomavirus vaccine in Scotland: a changing landscape Subscription

    In the UK, cervical cancer is the second most common cancer in women aged under 35 years. Human papillomavirus (HPV) types 16 and 18 (both high risk) are necessary precipitants in at least 70% of cervical cancers but may contribute to more than 80% of cervical cancers in Scotland. Both the prophylactic bivalent (Cervarix; GlaxoSmithKline) and quadrivalent (Gardasil; Merck) vaccines prevent infection with HPV types 16 and 18, and have been shown to induce avid and sustained neutralising ...

  • Patients with cancer and cancer survivors have an increased risk of adverse cardiovascular outcomes, including left ventricular (LV) dysfunction, heart failure (HF) and acute coronary syndromes.

    Cardiovascular side effects of cancer treatments Subscription

    The cardiovascular side effects of cancer treatments remain a challenge in oncologic care.

  • Micrograph of a group of tumor-specific T cells attacking a tumor cell

    T-cell therapies for cancer: from outsider to pharmaceutical darling Subscription

    Less than a decade ago, work on T-cell therapies by a handful of researchers was snubbed by their peers but now the field has exploded, money has poured in and there is a race on to see who can bring the technology to patients the quickest.

  • 3D MRI scan of a breast with breast cancer

    Improving long-term adjuvant anti-oestrogenic therapy for breast cancer Subscription

    Long-term (five years) adjuvant tamoxifen treatment for oestrogen receptor-positive, or ER-positive, breast cancer post-surgery is recognised as a major advance in healthcare. Clinical trials comparing standard and extended tamoxifen therapy found a major decrease in mortality occurred in the ten years following a decade of adjuvant therapy. Studies in premenopausal breast cancer patients showed that ovarian function suppression (OFS) an aromatase inhibitor (AI), ...

  • Close up of kidney with renal cell carcinoma

    Mammalian target of rapamycin (mTOR) inhibitors in solid tumours Subscription

    The phosphatidylinositol-3-kinase /protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway plays an important role in cell proliferation, growth, and angiogenesis.

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

steroids online

私たちの会社 adulttorrent.org

top 10 motivational books